A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

NCT05120960 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participant accrual

Conditions

Brain Tumor

Interventions

DRUG: tepotinib
DRUG: tepotinib plus osimertinib

Sponsor

M.D. Anderson Cancer Center